Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01741545 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 71
- Enrollment target
NCT01741545: Completed Phase 3 study, sponsored by Bristol-Myers Squibb.
NCT01741545 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 71 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01741545, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 71 participants
- Enrollment target
Study Summary
The primary objective for this study is to evaluate the proportion of subjects who achieve SVR12 (HCV RNA \< LLOQ (target not detected) at post-treatment follow-up Week 12 in subjects with Genotype(GT)-1b, -4 and GT-2, -3
Primary Outcome
SVR12 was defined as HCV ribonucleic acid (RNA) less than the lower limit of quantitation, target detected or target not detected at follow-up Week 12.
Interventions
- DRUG Ribavirin
- DRUG Daclatasvir
- BIOLOGICAL Pegylated-Interferon-lambda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2013-03-31 |
| Est. Completion | 2015-01-31 |
| Phase | Phase 3 |
What the finished NCT01741545 record still lists
NCT01741545 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 3 interventions - of which Ribavirin is the first listed.
NCT01741545 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01741545 about?
NCT01741545 is a clinical study titled "Safety and Efficacy Study in Subjects With Chronic HCV and Underlying Hemophilia". The primary objective for this study is to evaluate the proportion of subjects who achieve SVR12 (HCV RNA \< LLOQ (target not detected) at post-treatment follow-up Week 12 in subjects with Genotype(GT)-1b, -4 and GT-2, -3
What is the current status of trial NCT01741545?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 71 participants. The study started on 2013-03-31. Estimated completion is 2015-01-31.
What interventions are being tested in trial NCT01741545?
The interventions under investigation include: Ribavirin (DRUG), Daclatasvir (DRUG), Pegylated-Interferon-lambda (BIOLOGICAL).
Who is sponsoring clinical trial NCT01741545?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01741545's enrollment target sits among peer trials
71 1784th of 2000 higher than 216 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI